“FIB-4 ≥1.3 is correlated with increased DKD risk in T2D, but SGLT2i therapy that lowers FIB-4 attenuates this ”, d, vol. 3, no. 4, pp. 120–127, Dec. 2025, Accessed: Apr. 14, 2026. [Online]. Available: https://www.thediabzen.com/index.php/d/article/view/34